PRQR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ProQR Therapeutics NV (PRQR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential due to positive analyst sentiment and a promising RNA editing platform, the lack of immediate positive catalysts, weak financial performance, and no proprietary trading signals suggest holding off for now.
The MACD is positive but contracting, RSI is neutral at 61.779, and moving averages are converging, indicating no strong trend. Key support is at 1.682, and resistance is at 2.079. The stock is trading near its pivot level of 1.88, suggesting limited immediate upside.
Analyst coverage with an Outperform rating and a $9 price target, supported by strong preclinical data and a unique RNA editing platform addressing unmet medical needs.
No recent news or significant trading trends from hedge funds or insiders. Financial performance shows declining net income and EPS, with no recent congress trading data or influential figure activity.
In 2025/Q4, revenue increased by 6.14% YoY to $4.716M, but net income dropped by -4.14% YoY to -$8.92M, and EPS declined by -11.11% YoY to -0.08. Gross margin remained stable at 100%.
Oppenheimer analyst Kostas Biliouris rated the stock as Outperform with a $9 price target, citing strong preclinical data and a promising RNA editing platform addressing significant unmet medical needs.
